Dexcom Inc Stock Fundamentals
| DXCM Stock | USD 124.34 13.67 9.91% |
DexCom Inc fundamentals help investors to digest information that contributes to DexCom's financial success or failures. It also enables traders to predict the movement of DexCom Stock. The fundamental analysis module provides a way to measure DexCom's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DexCom stock.
At this time, DexCom's Net Income is very stable compared to the past year. As of the 27th of April 2024, Income Tax Expense is likely to grow to about 177.3 M, while Total Other Income Expense Net is likely to drop (2.1 M). DexCom | Select Account or Indicator |
DexCom Inc Company Operating Margin Analysis
DexCom's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current DexCom Operating Margin | 0.21 % |
Most of DexCom's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
DexCom Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, DexCom Inc has an Operating Margin of 0.2097%. This is 100.6% lower than that of the Health Care Equipment & Supplies sector and 100.53% lower than that of the Health Care industry. The operating margin for all United States stocks is 103.81% lower than that of the firm.
DexCom Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DexCom's current stock value. Our valuation model uses many indicators to compare DexCom value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DexCom competition to find correlations between indicators driving DexCom's intrinsic value. More Info.DexCom Inc is rated # 3 in return on equity category among related companies. It is rated # 4 in return on asset category among related companies reporting about 0.25 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for DexCom Inc is roughly 4.02 . At this time, DexCom's Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value DexCom by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DexCom's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DexCom's earnings, one of the primary drivers of an investment's value.DexCom Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.DexCom is currently under evaluation in operating margin category among related companies.
DexCom ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DexCom's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DexCom's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
DexCom Fundamentals
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0641 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 53.02 B | ||||
| Shares Outstanding | 396.03 M | ||||
| Shares Owned By Insiders | 0.36 % | ||||
| Shares Owned By Institutions | 99.64 % | ||||
| Number Of Shares Shorted | 11.77 M | ||||
| Price To Earning | 245.31 X | ||||
| Price To Book | 25.38 X | ||||
| Price To Sales | 14.49 X | ||||
| Revenue | 3.62 B | ||||
| Gross Profit | 1.88 B | ||||
| EBITDA | 916.7 M | ||||
| Net Income | 541.5 M | ||||
| Cash And Equivalents | 2.37 B | ||||
| Cash Per Share | 6.14 X | ||||
| Total Debt | 2.59 B | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 3.77 X | ||||
| Book Value Per Share | 5.37 X | ||||
| Cash Flow From Operations | 748.5 M | ||||
| Short Ratio | 4.32 X | ||||
| Earnings Per Share | 1.34 X | ||||
| Price To Earnings To Growth | 2.53 X | ||||
| Target Price | 151.32 | ||||
| Number Of Employees | 9.5 K | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 54.6 B | ||||
| Total Asset | 6.26 B | ||||
| Retained Earnings | 1.02 B | ||||
| Working Capital | 2.87 B | ||||
| Current Asset | 231.3 M | ||||
| Current Liabilities | 66.9 M | ||||
| Net Asset | 6.26 B |
About DexCom Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 18.4 M | 19.3 M | |
| Total Revenue | 3.6 B | 3.8 B | |
| Cost Of Revenue | 1.3 B | 1.4 B | |
| Stock Based Compensation To Revenue | 0.04 | 0.04 | |
| Sales General And Administrative To Revenue | 0.28 | 0.26 | |
| Research And Ddevelopement To Revenue | 0.14 | 0.13 | |
| Capex To Revenue | (0.07) | (0.07) | |
| Revenue Per Share | 9.38 | 9.85 | |
| Ebit Per Revenue | 0.17 | 0.17 |
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving against DexCom Stock
| 0.78 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.62 | IDXX | IDEXX Laboratories Financial Report 7th of May 2024 | PairCorr |
| 0.61 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
| 0.47 | CTSO | Cytosorbents Crp Financial Report 7th of May 2024 | PairCorr |
| 0.46 | GMED | Globus Medical Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out DexCom Piotroski F Score and DexCom Altman Z Score analysis. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.34 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.